Novo Nordisk receives positive opinion on Xultophy® (IDegLira) from the European regulatory authorities

Xultophy® is the intended brand name for IDegLira, the first once-daily single injection combination of Tresiba® (insulin degludec) and Victoza® (liraglutide), developed for the treatment of type 2 diabetes (Novo Nordisk)